GLP-1 Medications vs Weight Loss Peptides: Complete Comparison

GLP-1 Drugs vs Weight Loss Peptides: Comparison Table

GLP-1 Medications: Unmatched Efficacy for Weight Loss

GLP-1 receptor agonists are in a category of their own for pure weight loss. The STEP 1 trial showed 14.9% average body weight loss with semaglutide 2.4 mg over 68 weeks. The SURMOUNT-1 trial showed 22.5% with tirzepatide 15 mg. Retatrutide (a triple agonist in Phase III) showed 24.2% at 48 weeks in Phase II data. These results were previously thought impossible without bariatric surgery.

The mechanism is primarily appetite suppression — GLP-1 agonists reduce hunger centrally (hypothalamus) and peripherally (slowed gastric emptying). Patients consistently report dramatically reduced appetite, earlier satiety, and decreased food noise (obsessive thoughts about food). Additionally, these drugs improve insulin sensitivity, reduce hepatic fat, and have emerging cardiovascular benefits (MACE reduction in SELECT trial).

The trade-off: GI side effects are common (nausea in 40–50% of patients during titration), lean mass loss is a real concern (25–40% of weight lost can be muscle), and weight regain after discontinuation is significant (most patients regain 2/3 of lost weight within 1 year of stopping).

Weight Loss Peptides: Body Composition Focus

Research peptides used for weight loss work through fundamentally different mechanisms — primarily the growth hormone / IGF-1 axis rather than appetite suppression:

• GH secretagogues (ipamorelin + CJC-1295): Stimulate pituitary GH release, which selectively mobilizes visceral fat while preserving (and potentially increasing) lean muscle mass. Scale weight may not change much, but body composition improves — waist circumference decreases while muscle mass is maintained or increased. The effect is gradual (months, not weeks).
• Tesamorelin: The strongest evidence among GH peptides for fat reduction. FDA-approved for HIV-associated lipodystrophy. Clinical trials showed 15–20% reduction in visceral adipose tissue. Unlike GLP-1 drugs, it doesn't suppress appetite — it works through GH-mediated lipolysis.
• AOD-9604: Despite widespread marketing for fat loss, this GH fragment failed Phase III obesity trials. Not recommended as a primary fat-loss strategy based on current evidence.

The advantage over GLP-1s: GH peptides preserve lean mass (a major concern with GLP-1 drugs), have fewer GI side effects, and produce improvements in sleep, recovery, and skin quality alongside body composition changes. The disadvantage: they don't produce anywhere near the same magnitude of total weight loss.

Can You Combine GLP-1 Drugs and GH Peptides?

Some functional medicine physicians are beginning to combine GLP-1 agonists with GH peptides — using the GLP-1 for its appetite-suppressive weight loss while using ipamorelin/CJC-1295 to preserve lean mass and mitigate the muscle-loss concern. This is an emerging practice, not yet studied in clinical trials, but the pharmacological rationale is sound:

• GLP-1 drives caloric deficit through reduced appetite
• GH peptides provide anabolic support to preserve muscle during the caloric deficit
• The two mechanisms don't conflict — different receptor systems, no known interaction

Important caveats: This combination is off-label and has no RCT data. Both compounds have cost implications ($400–1,500+/month combined). Monitoring should include IGF-1, fasting glucose, and HbA1c — GH peptides and GLP-1 agonists have opposing effects on glucose metabolism that should be tracked. Any such protocol should be supervised by a physician experienced with both drug classes.